Giant-Cell Arteritis Market Outlook 2026–2030: Growth Trends, Market Dynamics And Emerging Opportunities

Global Giant-Cell Arteritis Market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Giant-Cell Arteritis Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The giant-cell arteritis market size has shown consistent expansion in recent years. This market is projected to expand from $1.12 billion in 2025 to $1.18 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.9%. The historical period’s growth can be attributed to factors such as aging population growth, reliance on corticosteroid therapy, improved rheumatology care, expansion of hospital-based treatment, and increased disease awareness.

The market size for giant-cell arteritis is anticipated to show consistent growth in the coming years. It is projected to expand to $1.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.3%. This expansion during the forecast period can be attributed to factors such as biologic drug approvals, growth in immunology research, improved diagnostic protocols, personalized vasculitis treatment, and the expansion of specialty clinics. Major trends influencing the forecast period include the increased adoption of biologic therapies, a rising focus on early and accurate diagnosis, expanded use of corticosteroid-sparing treatments, improved long-term disease monitoring, and growing awareness of vision loss prevention.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=60532318&type=smp&name=Giant-Cell%20Arteritis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Giant-Cell Arteritis Market Growth Backed By Core Demand Fundamentals

The giant-cell arteritis market is projected to expand due to an increasing focus on personalized medicine. This approach involves customizing medical care for each patient based on their unique attributes, including genetic makeup, lifestyle choices, and environmental influences. The rise of personalized medicine is driven by breakthroughs in genomics, biotechnology, and data analytics, which facilitate the development of targeted treatments that enhance effectiveness and minimize side effects for individuals. For giant-cell arteritis (GCA), personalized medicine offers the potential for tailored therapies, considering specific patient elements like genetic predispositions, immune profiles, and how the disease manifests. As an illustration, the U.S.-based non-profit Personalized Medicine Coalition (PMC) reported in February 2024 that personalized medicines constituted more than one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023, marking the fourth consecutive year for this trend. In 2023 alone, the FDA gave its nod to 16 novel personalized treatments for rare diseases, a notable increase from six such approvals in 2022. Furthermore, the 2023 approvals also included seven cancer drugs and three therapies for diverse other conditions. Consequently, the heightened emphasis on personalized medicine is fueling the expansion of the giant-cell arteritis market.

Giant-Cell Arteritis Market Segment Analysis And Revenue Potential

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

#Giant-Cell Arteritis Market Growth Trends: What’s Shaping The Future Outlook?

Major companies engaged in the giant-cell arteritis market are actively developing new treatments, such as biosimilars, to broaden available options and address the unmet medical needs of patients. A biosimilar is a biological drug that demonstrates high similarity to an already authorized biological product, possessing no clinically meaningful differences in terms of its safety, purity, or potency. For instance, in April 2024, Fresenius SE & Co. KGaA, a Germany-based healthcare provider, launched Tocilizumab-aazg in the US for managing chronic autoimmune conditions. This biosimilar has gained approval for ailments including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was founded on data from a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity against both US and EU reference tocilizumab across three patient populations.

Giant-Cell Arteritis Market Key Players Shaping Industry Direction

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

View The Full Giant-Cell Arteritis Market Report:

https://thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Giant-Cell Arteritis Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model